- Home
- Supplements
- Vitamin E
- Peyronie's Disease
Vitamin E for Peyronie's Disease
Vitamin E is the most tried supplement for Peyronie's — and controlled trials show it works no better than placebo. Guidelines recommend against it; early traction therapy during the active phase is where the real evidence sits.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not recommended — evidence does not support use
- Expected timeframe
- N/A
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. Vitamin E at 200-600 IU/day was one of the earliest oral treatments tried for Peyronie disease, on an antioxidant rationale, and it remains widely used - but controlled trials have not shown it outperforms placebo for plaque size, curvature or pain, and the American Urological Association guideline does not recommend oral vitamin E for Peyronie disease. Pain in the acute phase usually settles spontaneously, which makes uncontrolled reports of improvement unreliable.
- titration
- Not applicable
- starting dose
- Not applicable as an established treatment
Evidence
What the studies say
Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases
Paulis G, et al.
We can affirm that vitamin E can help to prevent the progression of PD. This study strongly supports the recommendation that the best approach for treating PD is multimodal therapy.
Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study
Safarinejad MR, et al.
This study did not show significant improvement in pain, curvature or plaque size in patients with PD treated with vitamin E, propionyl-L-carnitine, or vitamin E plus propionyl-L-carnitine compared with those treated with placebo. Note: an Expression of Concern (PMID 36626346) was issued for this paper in 2023.
Safety
Caveats
High-dose vitamin E carries bleeding risk and a signal of increased all-cause mortality in meta-analyses at 400 IU+. Using it delays traction therapy during the window it works best.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.